The Medicines Co. (MDCO)

20.79
NASDAQ : Health Technology
Prev Close 20.79
Day Low/High 0.00 / 0.00
52 Wk Low/High 19.55 / 41.57
Avg Volume 983.60K
Exchange NASDAQ
Shares Outstanding 73.86M
Market Cap 1.58B
EPS -9.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

The Medicines Company To Announce Third-Quarter 2018 Financial Results On November 8

The Medicines Company To Announce Third-Quarter 2018 Financial Results On November 8

The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Thursday, November 8, 2018, at 8:30 a.

The Medicines Company Announces Recommendation By Independent Data Monitoring Committee To Continue Inclisiran Phase III Trials Following Fourth Review Of Unblinded Data

The Medicines Company Announces Recommendation By Independent Data Monitoring Committee To Continue Inclisiran Phase III Trials Following Fourth Review Of Unblinded Data

The Medicines Company (NASDAQ:MDCO) today announced that the Independent Data Monitoring Committee (IDMC) for the ongoing inclisiran Phase III trials has recommended that the trials continue as designed and conducted, without modification.

The Medicines Company Reports Second-Quarter 2018 Results

The Medicines Company Reports Second-Quarter 2018 Results

The Medicines Company (NASDAQ:MDCO) today reported its financial results for the second quarter ended June 30, 2018.

The Medicines Company To Announce Second-Quarter 2018 Financial Results On August 1

The Medicines Company To Announce Second-Quarter 2018 Financial Results On August 1

The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Wednesday, August 1, 2018, at 8:30 a.

The Medicines Company Announces Recommendation By Independent Data Monitoring Committee To Continue Inclisiran Phase III Trials Following [Third] Review Of Unblinded Data

The Medicines Company Announces Recommendation By Independent Data Monitoring Committee To Continue Inclisiran Phase III Trials Following [Third] Review Of Unblinded Data

The Medicines Company (NASDAQ: MDCO) today announced that the Independent Data Monitoring Committee (IDMC) for the ongoing inclisiran Phase III trials has recommended that the trials continue as designed and conducted, without modification.

New Data Presented At The American Diabetes Association 78th Scientific Sessions® Reinforce The Potential Of The Medicines Company's Inclisiran In Patients With Diabetes

New Data Presented At The American Diabetes Association 78th Scientific Sessions® Reinforce The Potential Of The Medicines Company's Inclisiran In Patients With Diabetes

The Medicines Company (NASDAQ: MDCO) today announced the presentation of new data from a pre-specified, sub-group analysis of dosing, efficacy and safety of inclisiran in patients with diabetes from the ORION-1 Phase II trial at the American Diabetes...

The Medicines Company Announces Inclisiran Data Showing Significant Reductions In Potentially Harmful Subtypes Of Bad Cholesterol (Atherogenic Lipoproteins) Linked To Heart Attack And Stroke

The Medicines Company Announces Inclisiran Data Showing Significant Reductions In Potentially Harmful Subtypes Of Bad Cholesterol (Atherogenic Lipoproteins) Linked To Heart Attack And Stroke

The Medicines Company (NASDAQ:MDCO) today announced that the results of a pre-specified analysis of secondary endpoints from the ORION-1 Phase II study were presented at the 86 th European Atherosclerosis Society Congress (EAS 2018) and accepted for...

The Medicines Company Presents New Data At The National Lipid Association Scientific Sessions

The Medicines Company Presents New Data At The National Lipid Association Scientific Sessions

The Medicines Company (NASDAQ:MDCO) presented important new data and analyses from the ORION development program for inclisiran at the National Lipid Association (NLA) 2018 Scientific Sessions held in Las Vegas, NV.

First Week Of June 15th Options Trading For Medicines (MDCO)

Investors in Medicines Co saw new options become available this week, for the June 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MDCO options chain for the new June 15th contracts and identified one put and one call contract of particular interest.

The Medicines Company Reports First-Quarter 2018 Results

The Medicines Company Reports First-Quarter 2018 Results

The Medicines Company (NASDAQ: MDCO) today reported its financial results for the first quarter ended March 31, 2018.

The Medicines Company To Announce First-Quarter 2018 Financial Results On April 25

The Medicines Company To Announce First-Quarter 2018 Financial Results On April 25

The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Wednesday, April 25, 2018, at 8:30 a.

The Medicines Company Announces Chief Financial Officer Transition

The Medicines Company Announces Chief Financial Officer Transition

The Medicines Company (NASDAQ: MDCO) today announced the appointment of Christopher Visioli as Chief Financial Officer and Treasurer of the Company, effective immediately.

The Medicines Company To Participate In The Oppenheimer 28th Annual Healthcare Conference

The Medicines Company To Participate In The Oppenheimer 28th Annual Healthcare Conference

The Medicines Company (NASDAQ:MDCO) today announced that it will participate in the Oppenheimer 28 th Annual Healthcare Conference on Tuesday, March 20, 2018, in New York City, NY.

The Medicines Company Reaches Enrollment Target For ORION-10 Ahead Of Schedule

The Medicines Company Reaches Enrollment Target For ORION-10 Ahead Of Schedule

The Medicines Company (NASDAQ: MDCO) today announced that randomization of more than 1,500 patients in the ORION-10 trial in the United States has been completed in only 12 weeks - considerably beating its goal of 22 weeks.

The Medicines Company To Participate In The Cowen 38th Annual Health Care Conference

The Medicines Company To Participate In The Cowen 38th Annual Health Care Conference

The Medicines Company (NASDAQ:MDCO) today announced that it will participate in the Cowen 38 th Annual Health Care Conference on Tuesday, March 13, 2018, in Boston, MA.

The Medicines Company Appoints Dr. Sarah Schlesinger To Its Board Of Directors

The Medicines Company Appoints Dr. Sarah Schlesinger To Its Board Of Directors

The Medicines Company (NASDAQ: MDCO) today announced that its Board of Directors has appointed Dr.

The Medicines Company Reports Fourth-Quarter And Full-Year 2017 Business And Financial Results

The Medicines Company Reports Fourth-Quarter And Full-Year 2017 Business And Financial Results

The Medicines Company (NASDAQ:MDCO) today reported its financial results for the fourth quarter and full year ended December 31, 2017.

The Medicines Company Reaches Enrollment Target For ORION-9 Ahead Of Schedule

The Medicines Company Reaches Enrollment Target For ORION-9 Ahead Of Schedule

The Medicines Company (NASDAQ: MDCO) today announced that the target of 400 patients randomized in the ORION-9 trial has been exceeded in 10 weeks - considerably ahead of its anticipated recruitment goal of 24 weeks.

The Medicines Company To Host Conference Call And Webcast Discussing Fourth-Quarter And Full-Year 2017 Financial Results

The Medicines Company To Host Conference Call And Webcast Discussing Fourth-Quarter And Full-Year 2017 Financial Results

The Medicines Company (NASDAQ: MDCO) will host a conference call and webcast on Wednesday, February 21, 2018, at 8:30 a.

The Medicines Company To Participate In The Leerink Partners 7th Annual Global Healthcare Conference

The Medicines Company To Participate In The Leerink Partners 7th Annual Global Healthcare Conference

The Medicines Company (NASDAQ:MDCO) today announced that it will participate in the Leerink Partners 7 th Annual Global Healthcare Conference on Wednesday, February 14, 2018, in New York City.

Atlassian, AeroVironment, Granite Construction: 'Mad Money' Lightning Round

Atlassian, AeroVironment, Granite Construction: 'Mad Money' Lightning Round

Jim Cramer focuses on Atlassian, AeroVironment, Granite Construction, Ford Motor, U.S. Concrete, Chesapeake Energy.

The Bottom? Not So Fast: Cramer's 'Mad Money' Recap (Tuesday 2/6/18)

The Bottom? Not So Fast: Cramer's 'Mad Money' Recap (Tuesday 2/6/18)

Jim Cramer says we've cleaned out the bear den, but fundamental concerns, such as bond yields and wage inflation, still loom.

CORRECTING and REPLACING Inclisiran's First Pivotal Trial Achieves Target Enrollment Ahead of Schedule

CORRECTING and REPLACING Inclisiran's First Pivotal Trial Achieves Target Enrollment Ahead of Schedule

The end of the third sentence of the first paragraph of the release should read: then followed to the end of the study at 540 days (18 months) (instead of: then followed to the end of the study at 510 days (18 months)).

The Medicines Company Announces Closing Of Divestiture Of Infectious Disease Business Unit To Melinta Therapeutics

The Medicines Company Announces Closing Of Divestiture Of Infectious Disease Business Unit To Melinta Therapeutics

The Medicines Company (NASDAQ:MDCO) today announced the closing of the sale of its infectious disease business unit to Melinta Therapeutics, Inc.

The Medicines Company To Present At The 36th Annual J. P. Morgan Healthcare Conference

The Medicines Company To Present At The 36th Annual J. P. Morgan Healthcare Conference

The Medicines Company (NASDAQ:MDCO) today announced that its Chief Executive Officer, Clive Meanwell, M.

The Medicines Company To Host Investor Day On January 23, 2018

The Medicines Company To Host Investor Day On January 23, 2018

The Medicines Company (NASDAQ:MDCO) today announced that it will host an Investor Day on Tuesday, January 23, 2018, from 10:00 a.

MDCO: Insiders vs. Shorts

MDCO: Insiders vs. Shorts

The most recent short interest data was recently released for the 11/15/2017 settlement date, and Medicines Co is one of the most shorted stocks of the Russell 3000, based on 17.69 "days to cover" versus the median component at 4.67. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Melinta Up After Deal for Medicines' Infectious Disease Unit -- Biotech Movers

Melinta Up After Deal for Medicines' Infectious Disease Unit -- Biotech Movers

The New Haven, Conn.-based firm on Nov. 29 unveiled a deal to acquire The Medicines Co.'s infectious disease unit.

TheStreet Quant Rating: D (Sell)